aibioVeru regains compliance with Nasdaq minimum bid price rule
Tickers VERU
A Nasdaq letter received August 26, 2025 says Veru has regained compliance with the $1.00 minimum bid price rule and that the matter is closed. Nasdaq first wrote to the company about the bid price on August 29, 2024.
Key facts
- Company
- Veru Inc. (NASDAQ: VERU)
- News type
- Listings
- Primary source
- Veru Inc. 8-K (2025-08-27)
Veru Inc., a Wisconsin corporation based in Miami and listed on the Nasdaq Capital Market as VERU, reported in a Form 8-K dated August 26, 2025, and filed on August 27, that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC. The letter says the company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and that the matter is now closed. The 8-K is signed by Michele Greco, chief financial officer and chief administrative officer.
How the notice ran
The matter began with a letter received on August 29, 2024. Nasdaq told Veru that its common stock had failed to maintain a minimum bid price of $1.00 or more for 30 consecutive business days. The notice gave the company 180 calendar days from that date to regain compliance. The period was later extended to August 25, 2025.
The company received the compliance letter on August 26, 2025, one day after the extended deadline. The 8-K does not say when the bid price first closed at or above $1.00, how many consecutive business days it held there, or what the closing prices were. It does not say whether the company took any action to raise the price, such as a change to its share count, in order to meet the rule.
What the letter closes
Nasdaq's letter ends the minimum bid price matter. It does not say the company has met any other continued listing requirement, and the 8-K does not discuss other Nasdaq rules, such as stockholders' equity or market value tests. A closed bid price matter removes one specific deficiency. It does not show that the company has a stable path to meeting the rest of the listing standards.
The company's only disclosure in the 8-K is the Nasdaq letter. The filing reports no revenue, net loss, cash balance or share count, so readers cannot judge from it how much cash the company has against its spending.
The business behind the listing
The company's annual report for the fiscal year ended September 30, filed in December, describes Veru as a late clinical stage biopharmaceutical company focused on metabolic diseases, oncology and ARDS. Its two late-stage candidates are enobosarm, an oral selective androgen receptor modulator, and sabizabulin, a microtubule disruptor.
Enobosarm is being developed to augment fat loss and prevent lean mass loss in older, overweight or obese patients taking a GLP-1 drug. The report says the company is running a Phase 2b study called QUALITY in approximately 168 randomized patients, comparing 3mg and 6mg doses with placebo. The report describes the study as being conducted when it was written. Enobosarm is also being developed for metastatic breast cancer, but only "subject to the availability of sufficient funding."
Sabizabulin is being developed for hospitalized patients with viral-induced ARDS. The company says it does not intend to pursue that indication until it obtains funding from government grants, pharmaceutical partners or other third-party sources. The report also says the company will need substantial capital for its drug development and any commercialization efforts.
As of that December report, the company described the FC2 female condom as an FDA-approved commercial product and said it seeks to grow its sexual health program to help fund clinical development. The company's history includes a 1996 acquisition of worldwide rights to the first-generation female condom, a 2016 acquisition of Aspen Park Pharmaceuticals, Inc., and a 2017 name change from The Female Health Company to Veru Inc.
What the closing does not answer
The compliance letter does not address the business questions the annual report raises. The company still needs outside money for its late-stage programs, and the report says the breast cancer indication depends on funding. The 8-K gives no timetable for raising that money and no plan for the QUALITY study results.
For a shareholder, the letter is a procedural step. It confirms the bid price rule is no longer an open issue as of August 26, 2025. It does not report a change in the company's cash, its trial results or its funding plans, and it does not say whether the company expects to raise capital in the near term.